CN1274339C - 氨杞制剂及其制备方法和用途 - Google Patents
氨杞制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN1274339C CN1274339C CNB2003101162522A CN200310116252A CN1274339C CN 1274339 C CN1274339 C CN 1274339C CN B2003101162522 A CNB2003101162522 A CN B2003101162522A CN 200310116252 A CN200310116252 A CN 200310116252A CN 1274339 C CN1274339 C CN 1274339C
- Authority
- CN
- China
- Prior art keywords
- preparation
- ammonia
- liquid
- hours
- anqikang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 21
- 241000382353 Pupa Species 0.000 claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000004321 preservation Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 235000019628 coolness Nutrition 0.000 claims description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 7
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 208000002173 dizziness Diseases 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000003797 essential amino acid Substances 0.000 abstract description 2
- 235000020776 essential amino acid Nutrition 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 239000011149 active material Substances 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 98
- 229910021529 ammonia Inorganic materials 0.000 description 49
- 230000036541 health Effects 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 37
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 230000037396 body weight Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | n | 剂量(ml/kg.qb×10) | 血糖量(mmol/L) |
对照组(NS)消渴丸组氨杞康制剂 | 1010101010 | 200.1g102030 | 5.43±0.803.02±1.60***5.37±0.71*4.32±0.97***4.18±0.90*** |
组别 | N | 剂量(ml/kg.qb×12) | 胆固醇(mmol/L) | 甘油三酯(mmol/L) |
对照组(NS)月见草油组氨杞康制剂 | 1010101010 | 200.3102030 | 2.43±0.042.00±0.09***2.01±0.09***1.91±0.48***1.82±0.61** | 1.38±0.151.00±0.16***1.08±0.09***0.98±0.47**0.88±0.52*** |
组别 | n | 剂量(ml/kg体重.qd×7) | 吸收率 |
对照组环磷酰胺组氨杞康制剂组 | 1010101010 | 2020mg/kg102030 | 0.71±0.0390.63±0.031***0.77±0.023***0.80±0.021***0.84±0.036*** |
组别 | n | 剂量(ml/kg体重.qd×7) | HC50 |
对照组(NS)环磷酰胺组氨杞康制剂组 | 1010101010 | 2020mg/kg103030 | 79.51±9.0351.67±4.78***81.13±10.56*92.18±9.61***120.19±19.13*** |
组别 | n | 剂量(ml/kg体重.qd×7) | 足跖肿胀度(mm) |
对照组环磷酰胺组氨杞康制剂组 | 1010101010 | 2020mg/kg103030 | 0.23±0.050.15±0.04***0.31±0.07**0.45±0.08***0.53±0.13*** |
组别 | n | PHA(mg/ml) | 剂量(mg/ml) | Dpm | SI |
阴性对照组阳性对照组氨杞康制剂组 | 66666 | -1.251.251.251.25 | --0.0010.0030.01 | 1019.10±113.43**1025.09±592.2913382.90±2835.59**17114.65±801.13***20994.41±1905.40*** | 10.3613.2117.0320.94 |
组别 | n | 剂量(mg/ml) | DPM |
无血组生理盐水组环磷酰胺组氨杞康制剂组 | 66666 | --20g/ml0.010.03 | 5993±429***2694±1876231±893***1803±719***913±237*** |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101162522A CN1274339C (zh) | 2003-11-14 | 2003-11-14 | 氨杞制剂及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101162522A CN1274339C (zh) | 2003-11-14 | 2003-11-14 | 氨杞制剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1615931A CN1615931A (zh) | 2005-05-18 |
CN1274339C true CN1274339C (zh) | 2006-09-13 |
Family
ID=34760620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101162522A Expired - Lifetime CN1274339C (zh) | 2003-11-14 | 2003-11-14 | 氨杞制剂及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1274339C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106072667A (zh) * | 2016-06-20 | 2016-11-09 | 陆锦满 | 一种蚕蛹多肽养生膏 |
-
2003
- 2003-11-14 CN CNB2003101162522A patent/CN1274339C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1615931A (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1814167A (zh) | 一种用于糖尿病的保健品 | |
CN102578668B (zh) | 一种辅助降低血糖的饮料 | |
CN102613453A (zh) | 一种用于糖尿病患者的海洋生物型肠内营养制剂及其制备方法和用途 | |
CN107343889A (zh) | 一种用于治疗第1型或第2型糖尿病的蝙蝠蛾拟青霉菌发酵培养物 | |
CN103655599B (zh) | 多糖组合物及应用、含其的药物制剂 | |
CN1706281A (zh) | 一种能辅助降血糖、辅助降血脂的保健食品及其制备方法 | |
CN1762458A (zh) | 一种治疗高脂血症的药物及其制备方法 | |
CN102631494B (zh) | 一种提高免疫力、抗疲劳的中药组合物 | |
CN1051714C (zh) | 一种健脾开胃的中成药及其制备方法 | |
CN101322738A (zh) | 用檀香紫檀提取物治疗糖尿病的制备方法及其应用 | |
CN100464755C (zh) | 具有免疫调节作用的抗化学性肝损伤的中药制剂 | |
CN1274339C (zh) | 氨杞制剂及其制备方法和用途 | |
CN1857605A (zh) | 治疗慢性酒精中毒性肝病的药物及其制备方法 | |
CN1520831A (zh) | 养生护肝药物及其制备方法 | |
CN1233377C (zh) | 治疗单纯性肥胖的减肥中药 | |
CN104256618A (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN102631486B (zh) | 一种保健组合物 | |
CN102631488B (zh) | 一种提高免疫力、抗疲劳的中药组合物 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN1575803A (zh) | 一种库拉索芦荟提取物在预防和治疗糖尿病方面的应用方法 | |
CN102631487B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN1768778A (zh) | 决明子在制备促进排铅作用药品或保健品中的应用 | |
CN102631393B (zh) | 一种保健组合物 | |
CN1435209A (zh) | 治疗糖尿病的药物及其制备方法 | |
CN102631493B (zh) | 一种保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: XINJIANG QIKANG HABO UIGUR MEDICINE CO., LTD. Free format text: FORMER NAME: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG |
|
CP03 | Change of name, title or address |
Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. Address before: 830001 No. 36, Yanan Road, Urumqi, the Xinjiang Uygur Autonomous Region Patentee before: QIKANGHABO UGGR MEDICINE Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 830000 the Xinjiang Uygur Autonomous Region Urumqi hi tech Industrial Development Zone (new urban area) 1375 Patentee after: New Qikang Pharmaceutical Co.,Ltd. Address before: 830026 Yingbin Road, Urumqi, the Xinjiang Uygur Autonomous Region 625 Patentee before: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060913 |